Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-07-10
2010-12-07
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S243000, C514S249000, C514S266200, C514S314000, C514S369000, C514S379000, C514S394000, C514S452000, C514S465000, C514S469000, C544S105000, C544S183000, C544S284000, C544S353000, C546S169000, C548S183000, C548S241000, C548S304700, C549S366000, C549S435000, C549S467000
Reexamination Certificate
active
07846925
ABSTRACT:
The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R1, R2and n are as described in the description.
REFERENCES:
patent: 0 283 036 (1988-09-01), None
patent: 55-36429 (1980-03-01), None
patent: 55-45648 (1980-03-01), None
patent: 2000095770 (2000-04-01), None
patent: 02/051409 (2002-07-01), None
Prabhakar et al. “Synthesis and biological activity of novel thiazolidinediones” Bioorganic & Medicinal Chemistry Letters, 1998, vol. 8, Iss 6, pp. 2725-2730.
Janusz, John M. et al. “New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 3.7-tert-Butyl-2,3-dihydro-3,3-dimethylbenzofuran Derivates as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Variations at the 5 Position”, J. Med. Chem., vol. 41, No. 18, pp. 3515-3529, XP002223203 1998.
Brummond, Kay M. et al. “Solid-Phase Synthesis of BRL 49653”, J. Org. Chem., vol. 64, pp. 1723-1726 1999.
Cha, Jin Soon et al. “Exceptionally Facile Reduction of Acid Chlorides to Aldehydes by Sodium Tri-tert-butoxyaluminohydride”, J. Org. Chem., vol. 58, pp. 4732-4734 1993.
Fraser, James D. et al. “Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28”, Science, vol. 251, pp. 313-316 1991.
Fruman, David A. et al. “Phosphoinositide Kinases”, Annu. Rev. Biochem., vol. 67, pp. 481-507 1998.
Gerard, Craig et al. “Chemokines and Disease”, Nature Immunology, vol. 2, No. 2, pp. 108-115 2001.
Hirsch, Emilio et al. “Resistance to thromboembolism in PI3Kgamma-deficient mice”, The FASEB Journal, vol. 15, No. 11, pp. 2019-2021 2001.
Hirsch, Emilio et al. “Central Role for G Protein-Coupled Phosphoinositide 3-Kinase gamma in inflammation”, Science, vol. 287, No. 5455, pp. 1049-1053 2000.
Katso, Roy et al. “Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer”, Annu. Rev. Cell Dev. Biol, vol. 17, pp. 615-675 2001.
Laffargue, Muriel et al. “Phosphoinositide 3-Kinase gamma Is an Essential Amplifier of Mast Cell Function”, Immunity, vol. 16, No. 3, pp. 441-451 2002.
Lawlor, Margaret A. et al. “PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?”, Journal of Cell Science, vol. 114, No. 16, pp. 2903-2910 2001.
Leslie, Nick R. et al. “Phosphoinositide-Regulated Kinases and Phosphoinositide Phosphatases”, Chem. Rev., vol. 101, No. 8, pp. 2365-2380 2001.
Lopez-Ilasaca, Marco et al. “Phosphoinositide 3-Kinase gamma Is a Mediator of Gbetagamma-dependent Jun Kinase Activation”, The Journal of Biological Chemistry, vol. 273, No. 5, pp. 2505-2508 1998.
Panayotou, George et al. “Phosphatidyl-inositol 3-Kinase: a key enzyme in diverse signalling processes”, Trends in Cell Biology, vol. 2, pp. 358-360 1992.
Parker, Peter J. “PI 3-kinase puts GTP on the Rac”, Current Biology, vol. 5, No. 6, pp. 577-579 1995.
Petrov, Ognyan et al. “C-Formylation of some 2(3H)-Benzazolones and 2H-1,4-Benzoxazin-3(4H)-One”, Collect. Czech. Chem. Commun., vol. 62, pp. 494-497 1997.
Pages, Francoise et al. “Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling”, Nature, vol. 369, pp. 327-329 1994.
Rudd, Christopher E. “Upstream-Downstream: CD28 Cosignaling Pathways and T Cell Function”, Immunity, vol. 4, pp. 527-534 1996.
Stephens, Len et al. “Roles of PI3Ks in leukocyte chemotaxis and phagocytosis”, Curr. Opinion Cell Biol., vol. 14, No. 2, pp. 203-213 2002.
Stein, Robert C. et al. “PI3-kinase inhibition: a target for drug development?”, Molecular Medicine Today, vol. 6, No. 9, pp. 347-357 2000.
Thelen, Marcus et al. “Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes”, Proc. Natl. Acad. Sci., vol. 91, pp. 4960-4964 1994.
Toker, A. “Phosphoinositides and signal transduction”, Cell. Mol. Life Sci., vol. 59, No. 5, pp. 761-779 2002.
Vanhaesebroeck, B. et al. “Signaling by Distinct Classes of Phosphoinositide 3-Kinases”, Experimental Cell Research, vol. 253, vol. 1, pp. 239-254 1999.
Vanhaesebroeck, Bart et al. “Phosphoinositide 3-kinases: a conserved family of signal transducers”, TIBS, vol. 22, No. 7, pp. 267-272 1997.
Wymann, Matthias P. et al. “Lipids on the move: phosphoinositide 3-kinases in leukocyte function”, Immunology Today, vol. 21, No. 6, pp. 260-264 2000.
Yao, Ryoji et al. “Requirement for Phosphatidylinositol-3 Kinase in the Prevention of Apoptosis by Nerve Growth Factor”, Science, vol. 267, pp. 2003-2005 1995.
Hirsch et at. The Faseb Journal vol. 15 Sep. 2001, 2019-2021.
Brennan et at. Oncogene 2002, 21, 1263-1 271.
Martin, et al. Journal of Biological Chemistry, vol. 276, No. 19, Issue of May 11, 2001, pp. 15840-1 5849.
Johnson et al. Proc. Natl. Acad. Sci, U.S.A. vol. 94, pp. 3052-3057. Apr. 1997.
Benjamin et al. Journal of Virology. Apr. 1998, pp. 3221-3226.
Chock et al. PNAS, Jun. 20, 2000, vol. 97, No. 13, 71 18-7123.
Hirai et al. Oncogene 1997, 14, 3067-3072.
Kita et al. FEBS Letters 441(1998) 63-66.
Bierer et al. Proc. Natl. Acad. Sci., USA vol. 92, pp. 8808-881 2. Sep. 1995.
Downey et at. Microbes and Infection 5 (2003), 1293-1 298.
Yano et at Biochem. J. 1995, 312, 145-1 50.
Nienaber et al.The Journal of Clinical InvestigationOct. 2003 vol. 112 No. 7, 1067-1079.
Wymann et at. Biochemical Society Transactions (2003) vol. 31 Part 1, 275-280.
Plevin et al. Biochem. J. 1996, 318, pp. 965-971.
Roche et at.Oncogene2000, 19, 5083-5090.
Sawyers et al.Nature Review Cancervol. 2 Jul. 2002, 489-501.
Thelen et al.Thel Biochemical and Biophysical Research Communications, vol. 217, No. 3, 1995, pp. 1255-1262.
Vogt et al. PNAS, Feb. 15, 2000, vol. 97, No. 4, 1749-1 753.
Ward et at.Trends in Molecular Medecinevol. 7, Nol 0. Oct. 2001, pp. 455-462.
Weaver et at,Gastroenterology2001, 120, 1117-1127.
Weinstein et at. Journal of Leucocyte Biology vol. 67, Mar. 2000, 405-414.
Sheng et at. Gut 2003 52: 1472-1478.
Church Dennis
Gaillard Pascale
Grippi Vallotton Tania
Jiang Xuliang
Rueckle Thomas
Kosack Joseph R
Merck Serono SA
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Azolidinone-vinyl fused-benzene derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azolidinone-vinyl fused-benzene derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azolidinone-vinyl fused-benzene derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201438